Loading clinical trials...
Loading clinical trials...
The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objecti...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Cologne
NCT07356882 · Classical Hodgkin Lymphoma
NCT05362773 · Leukemia, Acute Myeloid, Myelodysplastic Syndromes, and more
NCT06848569 · Classical Hodgkin Lymphoma
NCT03697408 · Classical Hodgkin Lymphoma
NCT03480334 · Classical Hodgkin Lymphoma
University Hospital of Cologne
Cologne
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions